IMCD Group and Fabbrica Italiana Sintetici (FIS) sign active pharmaceutical ingredients (APIs) deal for Australia and New Zealand
Singapore: European distribution firm IMCD Group has partnered with Fabbrica Italiana Sintetici (FIS) for a wide range of active pharmaceutical ingredients, (APIs) including anxiolytics, anticonvulsants, antidepressants, analgesics, anti- inflammatory agents, antibacterials, antifungals, cardiovascular drugs, diuretics, oncological products and hormones for Australia and New Zealand.
The deal also covers countries including Hungary, Slovenia, Serbia, Croatia, Macedonia, Bosnia and Herzegovina and Albania. The successful partnership of the two companies already covers a large number of countries in Maghreb, Central and Eastern Europe, most CIS countries and Russia and Austria.
"We are delighted about this new partnership at IMCD Business Group Pharmaceuticals, as this is the first time IMCD has an agency for an API manufacturer in Australia and New Zealand," commented Ms Anne-Claire Bizet, development manager, European API, IMCD.
"APIs are a great complement to our comprehensive excipient portfolio, which makes our offer to the pharmaceutical market complete," she added.
Milan-based, FIS has custom synthesis as their core business, thus having the exclusive production of intermediates, advanced intermediates and APIs for leading pharmaceutical companies. FIS provides a wide array of integrated services to the customer, including process R&D, optimization, and scale-up facilities to support both validation and commercial launch.
